>
Powered by

New Meta-Analysis Presented at American College of Cardiology Strongly Supports RenalGuard(R) Use in Cardiovascular Interventional Procedures

A new meta-analysis presented this week at the American College of Cardiology further supports the ability of RenalGuard Therapy® to significantly reduce the incidence of acute kidney injury associated with cardiovascular interventional procedures compared to other methods of urine volume expansion. Moreover, findings from the analysis show the use of RenalGuard Therapy to be further associated with reduced risk of mortality, major adverse cardiovascular events, and the need for post-procedur

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox